Screening itself for disseminated intravascular coagulation may reduce mortality in sepsis: A nationwide multicenter registry in Japan

Thrombosis Research

Volumn 161, Issue , 2018, Pages 60-66

  Umemura, Yutaka ^a   Yamakawa, Kazuma ^b   Hayakawa, Mineji ^c   Hamasaki, Toshimitsu ^d   Fujimi, Satoshi ^b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA GENERAL MEDICAL CENTER   (Japan)

^c HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^d NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; HOSPITAL ADMISSION; HOSPITAL MORTALITY; HUMAN; INTENSIVE CARE; JAPAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCREENING; SEPSIS; SURVIVAL; CLINICAL TRIAL; MASS SCREENING; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; REGISTER; SURVIVAL ANALYSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COHORT STUDIES; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; HUMANS; JAPAN; MALE; MASS SCREENING; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; SEPSIS; SURVIVAL ANALYSIS;

EID: 85036525277     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2017.11.023     Document Type: Article

References (39)

1. Zeerleder, S., Hack, C.E., Wuillemin, W.A., Disseminated intravascular coagulation in sepsis. Chest 128 (2005), 2864–2875.
2. Levi, M., de Jonge, E., van der Poll, T., Sepsis and disseminated intravascular coagulation. J. Thromb. Thrombolysis 16 (2003), 43–47.
3. Bernard, G.R., Vincent, J.L., Laterre, P.F., LaRosa, S.P., Dhainaut, J.F., Lopez-Rodriguez, A. et al., Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344 (2001), 699–709.
4. Warren, B.L., Eid, A., Singer, P., Pillay, S.S., Carl, P., Novak, I. et al., High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286 (2001), 1869–1878.
5. Abraham, E., Reinhart, K., Opal, S., Demeyer, I., Doig, C., Rodriguez, A.L. et al., Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290 (2003), 238–247.
6. Abraham, E., Laterre, P.F., Garg, R., Levy, H., Talwar, D., Trzaskoma, B.L. et al., Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N. Engl. J. Med. 353 (2005), 1332–1341.
7. Wunderink, R.G., Laterre, P.F., Francois, B., Perrotin, D., Artigas, A., Vidal, L.O. et al., Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial. Am. J. Respir. Crit. Care Med. 183 (2011), 1561–1568.
8. Ranieri, V.M., Thompson, B.T., Barie, P.S., Dhainaut, J.F., Douglas, I.S., Finfer, S. et al., Drotrecogin alfa (activated) in adults with septic shock. N. Engl. J. Med. 366 (2012), 2055–2064.
9. Annane, D., Timsit, J.F., Megarbane, B., Martin, C., Misset, B., Mourvillier, B. et al., Recombinant human activated protein C for adults with septic shock: a randomized controlled trial. Am. J. Respir. Crit. Care Med. 187 (2013), 1091–1097.
10. Vincent, J.L., Ramesh, M.K., Ernest, D., LaRosa, S.P., Pachl, J., Aikawa, N. et al., A randomized, double-blind, placebo-controlled, phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit. Care Med. 41 (2013), 2069–2079.
11. Kienast, J., Juers, M., Wiedermann, C.J., Hoffmann, J.N., Ostermann, H., Strauss, R. et al., Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J. Thromb. Haemost. 4 (2006), 90–97.
12. Dhainaut, J.F., Yan, S.B., Joyce, D.E., Pettilä, V., Basson, B., Brandt, J.T. et al., Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J. Thromb. Haemost. 2 (2004), 1924–1933.
13. Yamakawa, K., Fujimi, S., Mohri, T., Matsuda, H., Nakamori, Y., Hirose, T. et al., Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study. Crit. Care, 15, 2011, R123.
14. Ogawa, Y., Yamakawa, K., Ogura, H., Kiguchi, T., Mohri, T., Nakamori, Y. et al., Recombinant human soluble thrombomodulin improves mortality and respiratory dysfunction in patients with severe sepsis. J. Trauma Acute Care Surg. 72 (2012), 1150–1157.
15. Yamakawa, K., Ogura, H., Fujimi, S., Morikawa, M., Ogawa, Y., Mohri, T. et al., Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis. Intensive Care Med. 39 (2013), 644–652.
16. Ferrer, R., Artigas, A., Suarez, D., Palencia, E., Levy, M.M., Arenzana, A. et al., Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. Am. J. Respir. Crit. Care Med. 180 (2009), 861–866.
17. Umemura, Y., Yamakawa, K., Ogura, H., Yuhara, H., Fujimi, S., Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta-analysis of randomized controlled trials. J. Thromb. Haemost. 14 (2016), 518–530.
18. Rhodes, A., Evans, L.E., Alhazzani, W., Levy, M.M., Antonelli, M., Ferrer, R. et al., Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 3 (2017), 304–377.
19. Taylor, F.B. Jr., Toh, C.H., Hoots, W.K., Wada, H., Levi, M., Scientific subcommittee on disseminated intravascular coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb. Haemost. 86 (2001), 1327–1330.
20. Gando, S., Iba, T., Eguchi, Y., Ohtomo, Y., Okamoto, K., Koseki, K. et al., A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit. Care Med. 34 (2006), 625–631.
21. Wada, H., Matsumoto, T., Hatada, T., Diagnostic criteria and laboratory tests for disseminated intravascular coagulation. Expert. Rev. Hematol. 5 (2012), 643–652.
22. Wada, H., Asakura, H., Okamoto, K., Iba, T., Uchiyama, T., Kawasugi, K. et al., Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb. Res. 125 (2010), 6–11.
23. Takemitsu, T., Wada, H., Hatada, T., Ohmori, Y., Ishikura, K., Takeda, T. et al., Prospective evaluation of three different diagnostic criteria for disseminated intravascular coagulation. Thromb. Haemost. 105 (2011), 40–44.
24. Van den Bruel, A., Cleemput, I., Aertgeerts, B., Ramaekers, D., Buntinx, F., The evaluation of diagnostic tests: evidence on technical and diagnostic accuracy, impact on patient outcome and cost-effectiveness is needed. J. Clin. Epidemiol. 60 (2007), 1116–1122.
25. Rodger, M., Ramsay, T., Fergusson, D., Diagnostic randomized controlled trials: the final frontier. Trials, 13, 2012, 137.
26. Bone, R.C., Balk, R.A., Cerra, F.B., Dellinger, R.P., Fein, A.M., Knaus, W.A. et al., Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101 (1992), 1644–1655.
27. Gando, S., Saitoh, D., Ogura, H., Mayumi, T., Koseki, K., Ikeda, T. et al., Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: results of a multicenter, prospective survey. Crit. Care Med. 36 (2008), 145–150.
28. Rosenbaum, P.R., Rubin, D.B., The central role of the propensity score in observational studies for causal effects. Biometrika 70 (1983), 41–55.
29. D'Agostino, R.B. Jr., D'Agostino, R.B. Sr., Estimating treatment effects using observational data. JAMA 297 (2007), 314–316.
30. Gayat, E., Pirracchio, R., Resche-Rigon, M., Mebazaa, A., Mary, J.Y., Porcher, R., Propensity scores in intensive care and anaesthesiology literature: a systematic review. Intensive Care Med. 36 (2010), 1993–2003.
31. Austin, P.C., Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis. Stat. Med. 30:35 (2016), 5642–5655.
32. Levi, M., Toh, C.H., Thachil, J., Watson, H.G., Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br. J. Haematol. 145 (2009), 24–33.
33. Di Nisio, M., Baudo, F., Cosmi, B., D'Angelo, A., De Gasperi, A., Malato, A. et al., Diagnosis and treatment of disseminated intravascular coagulation: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb. Res. 129 (2012), e177–84.
34. Wada, H., Thachil, J., Di Nisio, M., Mathew, P., Kurosawa, S., Gando, S. et al., Guidance for diagnosis and treatment of disseminated intravascular coagulation from harmonization of the recommendations from three guidelines. J. Thromb. Haemost. 11 (2013), 761–767.
35. Rangel-Frausto, M.S., Pittet, D., Costigan, M., Hwang, T., Davis, C.S. et al., The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 273:2 (Jan 11 1995), 117–123.
36. Yamakawa, K., Umemura, Y., Hayakawa, M., Kudo, D., Sanui, M., Takahashi, H. et al., Benefit profile of anticoagulant therapy in sepsis: a nationwide multicenter registry in Japan. Crit. Care, 20, 2016, 229.
37. Yoshimura, J., Yamakawa, K., Ogura, H., Umemura, Y., Takahashi, H., Morikawa, M. et al., Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis. Crit. Care, 3(19), 2015, 78.
38. Kalager, M., Zelen, M., Langmark, F., Adami, H.O., Effect of screening mammography on breast-cancer mortality in Norway. N. Engl. J. Med. 363 (2010), 1203–1210.
39. Doubeni, C.A., Corley, D.A., Quinn, V.P., Jensen, C.D., Zauber, A.G., Goodman, M. et al., Effectiveness of screening colonoscopy in reducing the risk of death from right and left colon cancer: a large community-based study. Gut 0 (2016), 1–8.